Cross-reactive human B cell and T cell epitopes between influenza A and B viruses

Virology Journal

Volumn 10, Issue , 2013, Pages

  Terajima, Masanori ^a   Babon, Jenny Aurielle B ^a   Co, Mary Dawn T ^a   Ennis, Francis A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cross reactive B cell epitopes; Cross reactive T cell epitopes; Fusion peptide; Hemagglutinin; Influenza A virus; Influenza B virus; Neuraminidase; Polymerase basic 1

Indexed keywords

EPITOPE;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CROSS REACTION; HUMAN; HUMAN CELL; IMMUNIZATION; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS B; REVIEW; SEQUENCE HOMOLOGY;

CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; VIRAL PROTEINS;

ANIMALIA; CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; INFLUENZA B VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 84880873907     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-244     Document Type: Review

References (70)

1. FAMILY ORTHOMYXOVIRIDAE. Cox NJ, Fuller F, Kaverin N, Klenk H-D, Lamb RA, Mahy BWJ, McCauley J, Nakamura K, Palese P, Webster R, Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR, Wickner RB, Virus Taxonomy Classification and Nomenclature of Viruses San Diego: Academic Press 2000 585 597
2. Influenza Viruses. Atmar RL, Manual of Clinical Microbiology. Volume 2 Washington, DC: ASM Press, Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, 9 2007 1340 1351
3. A distinct lineage of influenza A virus from bats. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, et al. Proc Natl Acad Sci U S A 2012 109 4269 4274 22371588
4. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Zhu X, Yu W, McBride R, Li Y, Chen LM, Donis RO, Tong S, Paulson JC, Wilson IA, Proc Natl Acad Sci U S A 2013 110 1458 1463 10.1073/pnas.1218509110 23297216
5. Influenza Virus. Hayden FG, Palese P, Clinical Virology Washington, DC: ASM Press, Richman DD, Whitley RJ, Hayden FG, 2 2002 891 920
6. Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Yamashita M, Krystal M, Palese P, Virology 1989 171 458 466 10.1016/0042-6822(89)90615-6 2763462 (Pubitemid 19210391)
7. Phylogenetic analysis of nucleoproteins suggests that human influenza A viruses emerged from a 19th-century avian ancestor. Gammelin M, Altmuller A, Reinhardt U, Mandler J, Harley VR, Hudson PJ, Fitch WM, Scholtissek C, Mol Biol Evol 1990 7 194 200 2319943 (Pubitemid 20129873)
8. Evolution and ecology of influenza A viruses. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y, Microbiol Rev 1992 56 152 179 1579108
9. The putative polymerase sequence of infectious salmon anemia virus suggests a new genus within the Orthomyxoviridae. Krossoy B, Hordvik I, Nilsen F, Nylund A, Endresen C, J Virol 1999 73 2136 2142 9971796 (Pubitemid 29098118)
10. Origin and evolution of influenza virus hemagglutinin genes. Suzuki Y, Nei M, Mol Biol Evol 2002 19 501 509 10.1093/oxfordjournals.molbev.a004105 11919291 (Pubitemid 34289425)
11. Dating the time of viral subtype divergence. O'Brien JD, She ZS, Suchard MA, BMC Evol Biol 2008 8 172 10.1186/1471-2148-8-172 18541033 (Pubitemid 351951572)
12. Orthomyxoviridae: The Viruses and Their Replication. Palese P, Shaw ML, Fields Virology Philadelphia: Lippincott Williams & Wilkins, Knipe DM, Howley PM, 2007 1648 1689
13. Molecular studies of influenza B virus in the reverse genetics era. Jackson D, Elderfield RA, Barclay WS, J Gen Virol 2011 92 1 17 10.1099/vir.0.026187-0 20926635
14. Structure of Influenza A, B and C Viruses. Ruigrok RWH, Textbook of INFLUENZA Malden: Blackwell Science, Nicholson KG, Webster RG, Hay AJ, 1998 29 42
15. Induction of Partial Specific Heterotypic Immunity in Mice by a Single Infection with Influenza a Virus. Schulman JL, Kilbourne ED, J Bacteriol 1965 89 170 174 14255658
16. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin- deficient, and J chain-deficient mice. Epstein SL, Lo CY, Misplon JA, Lawson CM, Hendrickson BA, Max EE, Subbarao K, J Immunol 1997 158 1222 1230 9013963 (Pubitemid 127469945)
17. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. O'Donnell CD, Wright A, Vogel LN, Wei CJ, Nabel GJ, Subbarao K, J Virol 2012 86 8625 8633 10.1128/JVI.00147-12 22674976
18. Influenza B virus PB1 protein; nucleotide sequence of the genome RNA segment predicts a high degree of structural homology with the corresponding influenza A virus polymerase protein. Kemdirim S, Palefsky J, Briedis DJ, Virology 1986 152 126 135 10.1016/0042-6822(86)90378-8 3754992 (Pubitemid 16065536)
19. Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. Mould JA, Paterson RG, Takeda M, Ohigashi Y, Venkataraman P, Lamb RA, Pinto LH, Dev Cell 2003 5 175 184 10.1016/S1534- 5807(03)00190-4 12852861 (Pubitemid 36827351)
20. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Stanekova Z, Vareckova E, Virol J 2010 7 351 10.1186/1743-422X-7-351 21118546
21. Broadly neutralizing antibodies against influenza viruses. Laursen NS, Wilson IA, Antiviral Res 2013 98 476 483 10.1016/j.antiviral.2013.03.021 23583287
22. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT, PLoS ONE 2007 2 1190 10.1371/journal.pone. 0001190 18030326 (Pubitemid 351638062)
23. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A, Proc Natl Acad Sci U S A 2007 104 246 251 10.1073/pnas.0609330104 17200302 (Pubitemid 46068017)
24. Heterosubtypic immunity to influenza A virus: where do we stand? Grebe KM, Yewdell JW, Bennink JR, Microbes Infect 2008 10 1024 1029 10.1016/j.micinf.2008.07.002 18662798
25. Cross-protective immunity to influenza A viruses. Epstein SL, Price GE, Expert Rev Vaccines 2010 9 1325 1341 10.1586/erv.10.123 21087110
26. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Krystal M, Elliott RM, Benz EW Jr, Young JF, Palese P, Proc Natl Acad Sci U S A 1982 79 4800 4804 10.1073/pnas.79.15.4800 6956892
27. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Chun S, Li C, Van Domselaar G, Wang J, Farnsworth A, Cui X, Rode H, Cyr TD, He R, Li X, Vaccine 2008 26 6068 6076 10.1016/j.vaccine.2008.09.015 19007587
28. Composition and functions of the influenza fusion peptide. Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA, Protein Pept Lett 2009 16 766 778 10.2174/092986609788681715 19601906
29. Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. Atassi MZ, Webster RG, Proc Natl Acad Sci U S A 1983 80 840 844 10.1073/pnas.80.3.840 6187004 (Pubitemid 13144450)
30. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, Kwang J, J Virol 2009 83 2553 2562 10.1128/JVI.02165-08 19109379
31. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Hashem AM, Van Domselaar G, Li C, Wang J, She YM, Cyr TD, Sui J, He R, Marasco WA, Li X, Biochem Biophys Res Commun 2010 403 247 251 10.1016/j.bbrc.2010.11.030 21078301
32. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Stanekova Z, Kiraly J, Stropkovska A, Mikuskova T, Mucha V, Kostolansky F, Vareckova E, Acta Virol 2011 55 61 67 10.4149/av-2011-01-61 21434706
33. Two distinct regions of HA2 glycopolypeptide of influenza virus hemagglutinin elicit cross-protective immunity against influenza. Janulikova J, Stanekova Z, Mucha V, Kostolansky F, Vareckova E, Acta Virol 2012 56 169 176 10.4149/av-2012-03-169 23043596
34. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. Liu X, Liu Y, Zhang Y, Chen Z, Tang Z, Xu Q, Wang Y, Zhao P, Qi Z, PLoS One 2013 8 58810 10.1371/journal.pone. 0058810 23527030
35. A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. Babon JA, Cruz J, Ennis FA, Yin L, Terajima M, J Virol 2012 86 9233 9243 10.1128/JVI.06325-11 22718815
36. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, Dutton RW, Swain SL, J Clin Invest 2012 122 2847 2856 10.1172/JCI63689 22820287
37. Memory CD4+ T cells: beyond «helper» functions. Boonnak K, Subbarao K, J Clin Invest 2012 122 2768 2770 10.1172/JCI65208 22820285
38. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Nat Med 2012 18 274 280 10.1038/nm.2612 22286307
39. Human memory CTL response specific for influenza A virus is broad and multispecific. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A, Hum Immunol 2000 61 438 452 10.1016/S0198-8859(00)00105-1 10773346 (Pubitemid 30238274)
40. Enumeration of haemagglutinin-specific CD8+ T cells after influenza vaccination using MHC class I peptide tetramers. Kosor Krnic E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Cecuk-Jelicic E, Kerhin-Brkljacic V, Gjenero-Margan I, Kaic B, Rakusic S, et al. Scand J Immunol 2008 67 86 94 18052968 (Pubitemid 350209590)
41. Highly conserved protective epitopes on influenza B viruses. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, et al. Science 2012 337 1343 1348 10.1126/science. 1222908 22878502
42. Stalking influenza. Eckert DM, Kay MS, Proc Natl Acad Sci U S A 2010 107 13563 13564 10.1073/pnas.1008672107 20660754
43. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nabel GJ, Fauci AS, Nat Med 2010 16 1389 1391 10.1038/nm1210-1389 21135852
44. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P, PLoS One 2012 7 43603 10.1371/journal.pone.0043603 22928001
45. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P, J Infect Dis 2013 207 98 105 10.1093/infdis/jis652 23087428
46. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ, Science 2010 329 1060 1064 10.1126/science.1192517 20647428
47. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P, MBio 2010 1 00018 00010 20689752
48. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, et al. Proc Natl Acad Sci U S A 2010 107 13701 13706 10.1073/pnas.1007465107 20615991
49. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA, Clin Infect Dis 2011 52 1003 1009 10.1093/cid/cir121 21460314
50. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Marcelin G, Sandbulte MR, Webby RJ, Rev Med Virol 2012 22 267 279 10.1002/rmv.1713 22438243
51. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu KW, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, et al. Vaccine 2010 28 5774 5784 10.1016/j.vaccine.2010.06.075 20621113
52. Sequence and structure alignment of paramyxovirus hemagglutinin- neuraminidase with influenza virus neuraminidase. Colman PM, Hoyne PA, Lawrence MC, J Virol 1993 67 2972 2980 8497041 (Pubitemid 23143664)
53. Antibody response in man to influenza virus neuraminidase following influenza. Kilbourne ED, Christenson WN, Sande M, J Virol 1968 2 761 762 5723531
54. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A, J Virol 2008 82 12241 12251 10.1128/JVI.01563-08 18842709
55. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Alexander J, Bilsel P, del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, Ishioka G, Kotturi MF, Botten J, Sidney J, et al. Hum Immunol 2010 71 468 474 10.1016/j.humimm.2010.02.014 20156506
56. A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection. Kosik I, Krejnusova I, Praznovska M, Polakova K, Russ G, Arch Virol 2012
57. Intracellular antibody neutralizes Listeria growth. Edelson BT, Unanue ER, Immunity 2001 14 503 512 10.1016/S1074-7613(01)00139-X 11371353 (Pubitemid 32520862)
58. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Sette A, Sidney J, Immunogenetics 1999 50 201 212 10.1007/s002510050594 10602880 (Pubitemid 30099525)
59. Several common HLA-DR types share largely overlapping peptide binding repertoires. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A, J Immunol 1998 160 3363 3373 9531296 (Pubitemid 28164729)
60. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, Larsen MV, Nielsen M, Lundegaard C, Tang ST, Dziegiel MH, et al. Vaccine 2007 25 2823 2831 10.1016/j.vaccine.2006.12.038 17254671 (Pubitemid 46420615)
61. Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. Terajima M, Cruz J, Leporati AM, Orphin L, Babon JA, Co MD, Pazoles P, Jameson J, Ennis FA, J Virol 2008 82 9283 9287 10.1128/JVI.01047-08 18614638
62. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. DiBrino M, Tsuchida T, Turner RV, Parker KC, Coligan JE, Biddison WE, J Immunol 1993 151 5930 5935 7504010 (Pubitemid 23340338)
63. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. Lee LY, LA H d, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, et al. J Clin Invest 2008 118 3478 3490 18802496
64. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Stoloff GA, Caparros-Wanderley W, Eur J Immunol 2007 37 2441 2449 10.1002/eji.200737254 17668898 (Pubitemid 47423615)
65. Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Babon JA, Cruz J, Orphin L, Pazoles P, Co MD, Ennis FA, Terajima M, Hum Immunol 2009 70 711 721 10.1016/j.humimm.2009.06. 004 19524006
66. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. Garcia-Canas V, Lorbetskie B, Girard M, J Chromatogr A 2006 1123 225 232 10.1016/j.chroma.2006.04.003 16677659 (Pubitemid 44150564)
67. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Garcia-Canas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M, Anal Chem 2007 79 3164 3172 10.1021/ac0621120 17361989 (Pubitemid 46640540)
68. Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Richards KA, Chaves FA, Alam S, Sant AJ, Vaccine 2012 31 219 225 10.1016/j.vaccine.2012.10.039 23099328
69. Toward a broadly protective influenza vaccine. Doherty PC, Kelso A, J Clin Invest 2008 118 3273 3275 18802488
70. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Alexander J, Bilsel P, del Guercio MF, Stewart S, Marinkovic-Petrovic A, Southwood S, Crimi C, Vang L, Walker L, Ishioka G, et al. Vaccine 2010 28 664 672 10.1016/j.vaccine.2009.10.103 19895924